Baraclude

Chronic Hepatitis B Infection, Viral Replication, Transaminases

Treatment

6 Active Studies for Baraclude

Treatment for

Chronic Hepatitis B Infection

What is Baraclude

EntecavirThe Generic name of this drug

Treatment SummaryEntecavir (marketed under the brand name Baraclude) is an oral antiviral medication used to treat hepatitis B infection. It works by stopping the virus from replicating and is more effective than other drugs used for the same purpose. Entecavir was approved by the U.S. FDA in 2005.

Baracludeis the brand name

image of different drug pills on a surface

Baraclude Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Baraclude

Entecavir

2005

Effectiveness

How Baraclude Affects PatientsEntecavir is a drug used to fight the hepatitis B virus. It works by blocking all three steps in the virus' replication process, which makes it more effective than the older hepatitis B drug, lamivudine.

How Baraclude works in the bodyEntecavir is a drug that blocks the HBV polymerase, which is responsible for replicating the virus. It does this by competing with the natural substrate deoxyguanosine triphosphate, preventing the polymerase from performing its 3 functions: base priming, reverse transcription of the negative strand, and synthesis of the positive strand of HBV DNA. When activated by kinases, entecavir can be incorporated into the DNA, making it impossible for the virus to replicate.

When to interrupt dosage

The amount of Baraclude is contingent upon the diagnosed disorder, including Chronic Hepatitis B, Viral Replication and Transaminases. The dosage likewise vacillates per the mode of administration highlighted in the table beneath.

Condition

Dosage

Administration

Transaminases

, 0.5 mg, 1.0 mg, 0.05 mg/mL

Oral, , Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral

Chronic Hepatitis B Infection

, 0.5 mg, 1.0 mg, 0.05 mg/mL

Oral, , Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral

Viral Replication

, 0.5 mg, 1.0 mg, 0.05 mg/mL

Oral, , Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Baraclude.

Common Baraclude Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Moderate

The metabolism of (R)-warfarin can be decreased when combined with Entecavir.

6-O-benzylguanine

Moderate

The metabolism of 6-O-benzylguanine can be decreased when combined with Entecavir.

8-azaguanine

Moderate

The metabolism of 8-azaguanine can be decreased when combined with Entecavir.

8-chlorotheophylline

Moderate

The metabolism of 8-chlorotheophylline can be decreased when combined with Entecavir.

9-Deazaguanine

Moderate

The metabolism of 9-Deazaguanine can be decreased when combined with Entecavir.

Baraclude Toxicity & Overdose RiskHealthy individuals have not experienced any adverse effects from taking up to 40 mg of entecavir in a single dose or up to 20 mg/day for up to 14 days. If an overdose occurs, the patient should be watched for signs of toxicity, and treated with the appropriate care if needed.

image of a doctor in a lab doing drug, clinical research

Baraclude Novel Uses: Which Conditions Have a Clinical Trial Featuring Baraclude?

Presently, three active studies are investigating the potential of Baraclude to inhibit Viral Replication, Chronic Hepatitis B and elevate Transaminase levels.

Condition

Clinical Trials

Trial Phases

Viral Replication

0 Actively Recruiting

Transaminases

0 Actively Recruiting

Chronic Hepatitis B Infection

6 Actively Recruiting

Phase 3, Phase 2